Tactile Systems Technology, Inc. Reaffirms Financial Guidance for the Full Year of 2024
May 06, 2024 at 05:00 pm
Share
Tactile Systems Technology, Inc. reaffirmed financial guidance for the full year of 2024. For the period, the company continue to expect total revenue in the range of $300 million to $305 million, representing growth of approximately 9% to 11% year-over-year. As a reminder, the company total revenue guidance range assumes that growth in both its lymphedema and airway clearance product lines will be in a similar range.
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company providing therapies for people with chronic disorders. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. The Company markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. The Company's Entre system is a basic pneumatic compression device. Kylee, its free mobile application, helps patients learn about lymphedema.
TACTILE SYSTEMS TECHNOLOGY, INC. 
